Nektar Therapeutics

As of June 30, 2026, Nektar Therapeutics carries a market capitalization of 2.08B, placing it among publicly traded companies globally. Its enterprise value stands at 1.55B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Nektar Therapeutics's next confirmed earnings release is scheduled for November 5, 2026.

As of June 30, 2026, Nektar Therapeutics has 34.13M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 31.01, and the price-to-book ratio stands at 2.64.

These figures are as of June 30, 2026. The EV/Sales ratio of 32.53 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 1.55B versus a market cap of 2.08B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Nektar Therapeutics maintains a current ratio of 10.42, meaning it holds 10.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 8.70, indicating elevated leverage, while an interest coverage ratio of -4.52 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -24.12, reflecting losses generated across the asset base. The company generates approximately 764,508.03 in revenue per employee across its workforce of 62.50, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Nektar Therapeutics recorded 56,019.20 in income tax expense. The company reported a pretax loss of -134.02M and -137.53M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Nektar Therapeutics's stock has declined approximately 37.43% over the past 52 weeks. The 50-day moving average sits at 52.20, while the 200-day moving average is 55.25.

Over the twelve months ended June 30, 2026, Nektar Therapeutics generated 47.78M in revenue and converted that into -137.53M in net income, yielding earnings per share of -5.67. EBITDA reached -122.58M, while operating income came in at -114.35M.

As of June 30, 2026, Nektar Therapeutics holds 599.00M in cash and equivalents against 68.76M in total debt, resulting in a net debt position of -34.37M. Total book value stands at 790.50M, with working capital of 585.07M providing operational flexibility.

Nektar Therapeutics produced -204.63M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -213,573.20 in capital expenditures, free cash flow totaled -204.85M - equivalent to -8.44 per share.

These figures cover the twelve months ended June 30, 2026. The operating margin of -239.32 and net profit margin of -287.84 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -13.83: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -45.11, meaning Nektar Therapeutics raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Nektar Therapeutics's most recent stock split took place on June 9, 2025 with a 15:1 split ratio.

As of June 30, 2026, Nektar Therapeutics has an Altman Z-Score of 2.91, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.